1. Home
  2. FVCB vs ALLO Comparison

FVCB vs ALLO Comparison

Compare FVCB & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FVCBankcorp Inc.

FVCB

FVCBankcorp Inc.

HOLD

Current Price

$16.05

Market Cap

229.7M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.71

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FVCB
ALLO
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
229.7M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FVCB
ALLO
Price
$16.05
$1.71
Analyst Decision
Buy
Strong Buy
Analyst Count
1
12
Target Price
$16.00
$8.27
AVG Volume (30 Days)
40.4K
7.1M
Earning Date
01-20-2026
03-12-2026
Dividend Yield
1.50%
N/A
EPS Growth
47.56
N/A
EPS
1.21
N/A
Revenue
$65,816,999.00
N/A
Revenue This Year
$9.22
N/A
Revenue Next Year
$7.13
N/A
P/E Ratio
$13.21
N/A
Revenue Growth
13.25
N/A
52 Week Low
$9.49
$0.86
52 Week High
$16.34
$3.78

Technical Indicators

Market Signals
Indicator
FVCB
ALLO
Relative Strength Index (RSI) 78.21 52.89
Support Level $15.61 $1.62
Resistance Level $15.97 $1.97
Average True Range (ATR) 0.42 0.16
MACD 0.08 -0.00
Stochastic Oscillator 100.00 42.72

Price Performance

Historical Comparison
FVCB
ALLO

About FVCB FVCBankcorp Inc.

FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, FVCbank which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: